Breaking News Instant updates and real-time market news.

MYL

Mylan

$38.15

-0.5 (-1.29%)

, VRX

Valeant

$13.46

-0.0103 (-0.08%)

10:20
05/19/17
05/19
10:20
05/19/17
10:20

USPTO sides with Mylan in challenge of Salix patent

The USPTO's Patent Trial and Appeal Board determined that claims 1 and 16 of the 8,865,688 patent owned by Dr. Falk Pharma GmbH are unpatentable. The patent relates to Salix Pharmaceuticals' Ulcerative Colitis treatment. Salix is owned by Valeant (VRX). The inter partes review of the patent was instituted following a challenge made by Mylan Pharmaceuticals (MYL).

MYL

Mylan

$38.15

-0.5 (-1.29%)

VRX

Valeant

$13.46

-0.0103 (-0.08%)

  • 19

    May

  • 22

    May

  • 06

    Jun

  • 24

    Aug

  • 03

    Sep

  • 09

    Oct

MYL Mylan
$38.15

-0.5 (-1.29%)

05/10/17
WELS
05/10/17
NO CHANGE
Target $40
WELS
Market Perform
Mylan deals masking 'weak' organic sales, says Wells Fargo
Wells Fargo analyst David Maris believes Mylan's deals are masking the company's contracting organic growth. When excluding deals, Mylan's total third party sales declined approximately 4% in Q1, with North American Sales down 11%, Europe down 1% and Rest of World up 11%, Maris tells investors in a post-earnings research note. He believes Mylan this morning reported an essentially in-line quarter on earnings, but that organic sales were "weak," particularly in North America. Maris has a Market Perform rating on Mylan with a $40 price target.
05/01/17
BMOC
05/01/17
INITIATION
Target $50
BMOC
Outperform
Mylan initiated with an Outperform at BMO Capital
BMO Capital analyst GaryNachman started Mylan with an Outperform rating and $50 price target. The company is one of the best positioned to navigate through the challenging generic trends over the longer term, the analyst argues.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Novartis results highlight tough pricing environment, says Wells Fargo
This morning's Q1 results from Novartis' (NVS) Sandoz division highlight the difficult U.S. generic price environment, Wells Fargo analyst David Maris tells investors in a research note. Sandoz experienced pricing erosion of 8% in the quarter, which represents the largest negative impact from pricing in recent quarters, Maris writes. He expects the negative U.S. pricing environment to impact including Mallinckrodt (MNK), Teva (TEVA), Mylan (MYL) and Perrigo (PRGO). Maris remains cautious on the pricing environment for generics.
04/11/17
WELS
04/11/17
NO CHANGE
WELS
Market Perform
Wells unsure of risk to Mylan from FDA warning letter
Wells Fargo analyst David Maris says he does not know what products, if any, are manufactured at Mylan's India-based plant that received the warning letter from the FDA. As such, the letter may have little or no immediate commercial risk, Maris tells investors in an intraday research note. The analyst questions whether the FDA will stop letting drugs from this facility into the U.S. He adds that to him, "nothing is more critical for a brand or generic drug company than being able to ensure that its products are safe and effective." Maris keeps a Market Perform rating on Mylan.
VRX Valeant
$13.46

-0.0103 (-0.08%)

05/19/17
DBAB
05/19/17
NO CHANGE
Target $18
DBAB
Hold
Deutsche Bank 'warming up' to Valeant story
In a research note titled "Warming up to VRX," Deutsche Bank analyst Gregg Gilbert says that while Valeant Pharmaceuticals is "not out of the woods," the worst fears may be subsiding. The analyst continues to view the company's near-term setup as "encouraging." Valeant's 2017 outlook seems reachable, asset sales in the near- and medium-term seem likely, and the recent refinancing provided more time and flexibility for the company to deal with its issues, Gilbert tells investors. He also believes the worst case for Xifaxan of near-term generic competition "seems to be off the table for now." The analyst keeps a Hold rating on Valeant with an $18 price target. The drugmaker closed yesterday up 22c to $13.47.
05/11/17
WELS
05/11/17
NO CHANGE
Target $9
WELS
Underperform
Valeant estimates reduced on weakening fundamentals at Wells Fargo
Wells Fargo analyst David Maris said the reaction to Valeant's guidance is too positive and notes leverage has increased, most businesses missed his forecasts, and the increase in EBITDA guidance was due to changes in how it accounts for foreign exchange. The analyst lowered estimates and reiterated his Underperform rating given the company's deteriorating fundamentals, adding that he expects the recent share strength to be temporary. However, he increased his price target on the shares to $9 from $8, noting Valeant's Q1 showed a "dramatic decline" in working capital.
05/09/17
JPMS
05/09/17
NO CHANGE
JPMS
Neutral
Valeant's road to recovery remains long, says JPMorgan
JPMorgan analyst Chris Schott finds today's rally in Valeant Pharmaceuticals unsurprising as EBITDA guidance was raised following significant cuts over the past year. That said, the analyst continues to see a "long road to recovery for the story." He keeps a Neutral rating on the shares. Valeant is up 18%, or $1.79, to $11.50 in midday trading.
05/09/17
WELS
05/09/17
NO CHANGE
WELS
Underperform
Valeant key products continue to underperform, says Wells Fargo
Following the company's Q1 results, Wells Fargo analyst David Maris says Valeant Pharmaceuticals' key products continue to underperform. Valeant's decision to highlight in its press release the EBITDA raise of 1.3% is understandable, as this is better than the recent trend, but the $50M raise is relative to approximately $28.9B of total debt, Maris tells investors in a research note. Key products and areas such as Xifaxan and Bausch + Lomb continue to underperform, the analyst contends. He keeps an Underperform rating on Valeant with an $8 price target. The stock in morning trading is up 15%, or $1.48, to $11.19.

TODAY'S FREE FLY STORIES

INTU

Intuit

$127.16

1.78 (1.42%)

14:49
05/23/17
05/23
14:49
05/23/17
14:49
Options
Intuit options imply 5.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

HON

Honeywell

$131.92

0.08 (0.06%)

14:47
05/23/17
05/23
14:47
05/23/17
14:47
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

CNQ

Canadian Natural

$31.04

-0.08 (-0.26%)

, RDS.A

Royal Dutch Shell

$55.22

-0.0499 (-0.09%)

14:45
05/23/17
05/23
14:45
05/23/17
14:45
Periodicals
Breaking Periodicals news story on Canadian Natural, Royal Dutch Shell, Royal Dutch Shell »

Shell to sell entire 8.8%…

CNQ

Canadian Natural

$31.04

-0.08 (-0.26%)

RDS.A

Royal Dutch Shell

$55.22

-0.0499 (-0.09%)

RDS.B

Royal Dutch Shell

$56.96

-0.0576 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRE

Sempra Energy

$113.64

0.77 (0.68%)

14:45
05/23/17
05/23
14:45
05/23/17
14:45
Periodicals
CBS LA teases 'shocking' report on Sempra's Aliso Canyon gas leak »

CBS Los Angeles tweeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

X

U.S. Steel

$20.43

0.96 (4.93%)

14:45
05/23/17
05/23
14:45
05/23/17
14:45
Technical Analysis
Technical Analysis: U.S. Steel breaking out of downtrend, levels to watch »

The stock is rallying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$131.70

-0.14 (-0.11%)

14:42
05/23/17
05/23
14:42
05/23/17
14:42
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says thinks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

X

U.S. Steel

$20.39

0.9169 (4.71%)

14:40
05/23/17
05/23
14:40
05/23/17
14:40
Options
US Steel calls outpace puts nearly 3:1 as shares rally »

US Steel calls outpace…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$42.83

-0.75 (-1.72%)

14:39
05/23/17
05/23
14:39
05/23/17
14:39
Downgrade
Momo rating change  »

Momo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AZO

AutoZone

$596.00

-63.49 (-9.63%)

14:39
05/23/17
05/23
14:39
05/23/17
14:39
Recommendations
AutoZone analyst commentary  »

AutoZone weakness an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

HON

Honeywell

$131.63

-0.21 (-0.16%)

14:37
05/23/17
05/23
14:37
05/23/17
14:37
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says he…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

ALXN

Alexion

$115.42

1.58 (1.39%)

14:31
05/23/17
05/23
14:31
05/23/17
14:31
Recommendations
Alexion analyst commentary  »

Alexion should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

RBS

RBS

$6.95

0.09 (1.31%)

14:30
05/23/17
05/23
14:30
05/23/17
14:30
Options
Royal Bank of Scotland sees put buying »

Royal Bank of Scotland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

HON

Honeywell

$131.98

0.14 (0.11%)

14:29
05/23/17
05/23
14:29
05/23/17
14:29
Hot Stocks
Honeywell says spinoff of aerospace is 'intriguing concept' »

This comment was made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HON

Honeywell

$132.08

0.235 (0.18%)

14:25
05/23/17
05/23
14:25
05/23/17
14:25
Hot Stocks
Honeywell to shape portfolio changes over next 2-3 years »

Comments are from EPG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HLF

Herbalife

$69.44

-4 (-5.45%)

14:21
05/23/17
05/23
14:21
05/23/17
14:21
Technical Analysis
Technical Analysis: Herbalife falls on report China executive departs »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$80.28

10.21 (14.57%)

14:20
05/23/17
05/23
14:20
05/23/17
14:20
Options
Newsbots go Bungee jumping this afternoon »

Newsbots go Bungee…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$122.18

0.52 (0.43%)

14:18
05/23/17
05/23
14:18
05/23/17
14:18
Hot Stocks
United Technologies CEO not interested in split »

Speaking at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

MOMO

Momo

$42.83

-0.75 (-1.72%)

14:17
05/23/17
05/23
14:17
05/23/17
14:17
Recommendations
Momo analyst commentary  »

Momo price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

$NSD

NASDAQ Market Internals

14:17
05/23/17
05/23
14:17
05/23/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
05/23/17
05/23
14:16
05/23/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIG

AIG

$61.56

0.175 (0.29%)

14:12
05/23/17
05/23
14:12
05/23/17
14:12
Hot Stocks
A.M. Best affirms AIG credit ratings, removes from under review »

A.M. Best has removed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BWLD

Buffalo Wild Wings

$150.60

-2 (-1.31%)

14:11
05/23/17
05/23
14:11
05/23/17
14:11
Technical Analysis
Technical Analysis: Buffalo Wild Wings trades at session lows »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$131.96

0.12 (0.09%)

14:11
05/23/17
05/23
14:11
05/23/17
14:11
Earnings
Honeywell backs FY17 EPS view $6.90-$7.10, consensus $7.09 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HON

Honeywell

$131.98

0.14 (0.11%)

14:08
05/23/17
05/23
14:08
05/23/17
14:08
Earnings
Honeywell backs Q2 EPS view $1.75-$1.80, consensus $1.78 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

WRB

W. R. Berkley

$67.93

0.26 (0.38%)

14:05
05/23/17
05/23
14:05
05/23/17
14:05
Hot Stocks
Ca. Insurance Commissioner announces $12M settlement with W. R. Berkley »

California Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.